SITC 2019

An anti-carcinoma monoclonal antibody (mAb) NEO-201 can also target and eliminate human immunosuppressive regulatory T cells (Tregs) Authors: Philip M. Arlen, MD; Kwong Y. Tsang, PhD; Massimo Fantini, PhD; Justin M. David; M Maria Morelli, MD; Christina M. Annunzata,...

Immuno-Oncology Europe 2019

Discovery and Development of Monoclonal Antibodies Targeting Tumor Neo-Epitopes Presented by Dr. Philip Arlen President and CEO, Precision Biologics, Inc, United States of America An allogeneic cancer vaccine developed from human tumors surgically resected had...

2019 ASCO Annual Meeting

Abstract Title: Phase 1 with expansion cohorts in a study of NEO-201 in adults with chemo-resistant solid tumors. Session Title/Date/Time: Poster Session: Developmental Immunotherapy and Tumor Immunobiology, 6/1/2019, 8:00 AM-11:00 AM May 31 – June 4, 2019 at the...